13484-66-7

Usage

Uses

Used in Pharmaceutical Industry:
[(2R,3R,4R,5R)-5-[6-(benzylamino)purin-9-yl]-3,4-dihydroxy-oxolan-2-yl ]methoxyphosphonic acid is used as an antiviral agent for the treatment of HIV/AIDS and chronic hepatitis B. It is utilized for its ability to inhibit the replication of the virus, slowing down the spread of the infection and reducing the progression of the disease.
Used in Combination Therapy:
[(2R,3R,4R,5R)-5-[6-(benzylamino)purin-9-yl]-3,4-dihydroxy-oxolan-2-yl ]methoxyphosphonic acid is used as a component in combination antiretroviral therapy for the effective management of HIV/AIDS. Its inclusion in combination therapy helps to suppress the replication of the virus more effectively than single-agent treatments, leading to better patient outcomes and reduced risk of viral resistance.

InChI:InChI=1/C17H20N5O7P/c23-13-11(7-28-30(25,26)27)29-17(14(13)24)22-9-21-12-15(19-8-20-16(12)22)18-6-10-4-2-1-3-5-10/h1-5,8-9,11,13-14,17,23-24H,6-7H2,(H,18,19,20)(H2,25,26,27)/p-2/t11-,13-,14-,17-/m1/s1

Upstream product

• 1159680-48-4 6-N-benzyladenylyl(2'-5')-6-N-benzyladenosine 
• 1159680-49-5 6-N-benzyladenylyl(2'-5')-6-N-benzyladenylyl(2'-5')-6-N-benzyladenylyl-(2'-5')-6-N-benzyladenosine 
• 4294-16-0 N₆-Benzyladenosine 
• 193898-79-2 N⁶-benzyladenylyl(2'-5')-N⁶-benzyladenylyl(2'-5')-N⁶-benzyladenosine 

Downstream Products

• 1055041-51-4 C₃₀H₃₆N₆O₁₄P₂ 

Relevant academic research and scientific papers

Identification of non-lipid LPA3 antagonists by virtual screening

In the present study, we utilized virtual screening to identify LPA3 antagonists. We have developed a three-point structure-based pharmacophore model based on known LPA3 antagonists. This model was used to mine the NCI database. Docking, pharmacophore development, and database mining produced new, non-lipid leads. Experimental testing of seven computationally selected pharmacophore hits produced one potentiator and three antagonists, one of which displays both LPA3 selectivity and nanomolar potency. Similarity searching in the ChemBridge database using the most promising lead as the search target produced four additional LPA3 antagonists and a potent dual LPA1&2 antagonist.

Preparation of (2?-5?)-oligonucleotides based on 6-N- benzylaminopurineriboside using the Spicaria violacea fungal enzyme complex

A method for chemico-enzymatic synthesis of (2?-5?)-oligonucleotides with 6-N-benzylaminopurineriboside as the nucleoside units was proposed. The method consisted of enzymatic hydrolysis of the oligonucleotides with mixed (2?-5?)-(3?-5?)-phosphodiesterbonds that were prepared by polymerization of 6-N-benzyladenosine-2?(3?)-monophosphate by using (3?-5?)-specific nuclease and phosphatase contained in the filtrate of culture medium of the mycelial fungus Spicaria violacea.